Wockhardt Shares Surge Up to 10% Following Fourth-Quarter Profit Turnaround

Wockhardt Ltd Shares Rise 10% After Reporting Consolidated Net Profit

Wockhardt Ltd shares surged 10% on May 5, a day after the pharmaceuticals firm reported a consolidated net profit of Rs 164 crore in the fourth quarter ended March 31, 2026. This significant increase in profit marks a stark contrast to the company's corresponding period in the previous fiscal, where it posted a consolidated net loss of Rs 45 crore.

The company's consolidated revenue from operations stood at Rs 965 crore, a notable increase from Rs 743 crore in the year-ago period. This growth in revenue is a positive indicator of the company's financial health. At 9:35 am on May 5, Wockhardt shares were trading 8% higher at Rs 1,540.8 apiece.

However, the company's total expenses in the fourth quarter were higher at Rs 843 crore as compared to Rs 780 crore in the same period a year ago. Despite this, the company's profitability in the quarter was supported by higher scale in emerging markets and disciplined cost control, even as R&D investments remained steady.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Looking at the full year, Wockhardt's consolidated net profit was at Rs 199 crore in FY26, a significant improvement from the consolidated net loss of Rs 57 crore in FY25. The company's consolidated revenue from operations in FY26 was at Rs 3,373 crore, compared to Rs 3,012 crore in FY25. This indicates a steady growth in revenue over the past year.

The company's board has approved the proposal for raising of funds, which will be done through the issue of equity shares, securities convertible into equity shares, or non-convertible securities, among other methods. Exceptional items largely netted out at the full-year level, with Q4 seeing a Rs 22 crore exceptional charge, while FY26 benefited from a credit linked to settlement proceeds from Dr Reddy’s Laboratories, partly offsetting restructuring and regulatory-related charges earlier in the year.